Immune system stimulation against tumor antigens

Immune system stimulation against tumor antigens is not a specific molecule or receptor, but rather describes a broad therapeutic strategy in cancer immunotherapy. This approach involves activating or enhancing the body's immune response—particularly T cells and other effector cells—to recognize and destroy cancer cells that express unique or overexpressed proteins known as tumor-associated antigens. Key mechanisms include checkpoint inhibition (blocking inhibitory receptors like CTLA‑4 or PD‑1 on T cells), monoclonal antibodies that flag cancer cells for destruction, bispecific antibodies that bring immune and cancer cells together, therapeutic vaccines exposing the immune system to tumor antigens, and adoptive cell transfer where patient-derived immune cells are engineered for enhanced anti-tumor activity[3][4]. Because this entry refers to a process rather than a discrete molecular target, it is not considered an individual druggable target but encompasses multiple targets within the broader context of immuno-oncology.

Checkpoint inhibition to enhance T cell activation against tumors; Monoclonal antibody-mediated targeting of tumor-associated antigens